Health TrialsbyHealthPanel

REDCURE Registry for Chronic Kidney Disease (CKD) Anemia

ConditionCKD Anemia
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNabiqasim Industries (Pvt) Ltd

About this trial

A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)

Patients on hemodialysis (HD) or peritoneal dialysis (PD)

Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent

Disqualifiers

Acute Kidney Injury (AKI) without underlying chronicity

Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)

Refusal or inability to provide consent

Current enrollment in an interventional trial that restricts real-world data collection

Trial population

patients with Chronic Kidney Disease (CKD) anemia requiring anemia treatment

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • Daprodustat

    Drug

    Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug

Treatment groups

384 Participants
are divided into 1 treatment group
Group A: Daprodustat arm for CKD anemia patients1 intervention

Trial outcomes

Primary outcomes

1

Serum hemoglobin levels

Hemoglobin response to therapy

Time frame
3 months

Secondary outcomes

1

Frequency of MACE ( Major Adverse Cardiovascular Events)

MACE events: * Unstable angina requiring hospitalization * Non-fatal MI * Non-fatal stroke * Cardiovascular death * Other adverse events * Hospitalization episodes . Mortality * Optional patient-reported outcomes (fatigue, functional status)

Time frame
3 months

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Nabiqasim Industries (Pvt) Ltd

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: